Significant progress has been made in reducing the risk of pathogen transmission to transfusion recipients. Nonetheless, there remains a continuing risk of transmission of viruses, bacteria, protozoa, and prions to recipients. These include many of the viruses for which specific screening tests exist as well as pathogens for which testing is currently not being done, including various species of bacteria, babesiosis, variant Creutzfeld-Jacob disease, hepatitis A virus, human herpes virus 8, chikungunya virus, Chagas disease, and malaria. Pathogen inactivation (PI) technologies potentially provide an additional way to protect the blood supply from emerging agents and also provide additional protection against both known and as-yet-unidentified agents. However, the impact of PI on product quality and recipient safety remains to be determined. The purpose of this consensus conference was to bring together international experts in an effort to consider the following issues with respect to PI: implementation criteria; licensing requirements; blood service and clinical issues; risk management issues; cost-benefit impact; and research requirements. These proceedings are provided to make available to the transfusion medicine community the considerable amount of important information presented at this consensus conference.

中文翻译：

---

共识会议论文集：关于新技术的病原体灭活决策。

在降低病原体向输血接受者传播的风险方面取得了重大进展。尽管如此，仍然存在将病毒、细菌、原生动物和朊病毒传播给接受者的持续风险。其中包括许多存在特定筛查测试的病毒以及目前尚未进行测试的病原体，包括各种细菌、巴贝斯虫病、变异克雅氏病、甲型肝炎病毒、人类疱疹病毒 8、基孔肯雅病毒、恰加斯病和疟疾。病原体灭活 (PI) 技术可能提供一种额外的方法来保护血液供应免受新出现的病原体的侵害，并且还提供针对已知和尚未鉴定的病原体的额外保护。然而，PI 对产品质量和接受者安全的影响仍有待确定。本次共识会议的目的是将国际专家聚集在一起，努力考虑与 PI 相关的以下问题：实施标准；许可要求；血液服务和临床问题；风险管理问题；成本效益影响；和研究要求。提供这些会议记录是为了向输血医学界提供在本次共识会议上提出的大量重要信息。